Increasing Demand Variability

Growth in the Specialty Pharma segment and targeted therapies, rise in chronic diseases, geopolitical shocks, and fast-changing consumer wellness trends are driving unprecedented demand variability [5]. Outbreaks and preventive healthcare innovations further fragment markets, forcing manufacturers to pivot production in real time. Traditional factories can’t keep up — but agile, modular ones can. They pivot in real time, adapt to shifting needs, and handle growing SKU complexity with ease.

Increasing Number of Products

SKU counts in pharma and wellness are exploding — and with them, the need for flexible production. Top pharma firms now manage 2x more SKUs than in 2015, yet 40% of factory capacity sits idle due to rigid, outdated workflows.

This SKU surge is fueled by chronic diseases, targeted therapies, and personalized wellness. Today, 70% of new drug launches target niche conditions, demanding high-mix, agile manufacturing — something traditional plants simply weren’t built for.

Precision Medicine getting Unlocked

Unlocking $175B+ precision medicine market demands agility in production. While all other pieces are in place viz. diagnostics, genomics, microbiome, biomarkers etc., what is missing is an agile manufacturing solution. It also requires coupling digital technologies with physical factories to compound, produce, pack and dispatch individualized products at scale. Traditional CDMOs and pharma factories struggle with such a high product mix leading to long delays and high costs for innovators.

Leumas’ modular, cyber-physical manufacturing systems—designed for autonomous operation and built-in containment—are purpose built to unlock the next generation of targeted and precision therapies, including those involving HPAPI molecules.

By combining:

  • Macro-containment technology due to continuous, closed loop manufacturing
  • Reprogrammable, unmanned robotic lines for high-mix manufacturing,
  • And a dramatically lower CapEx footprint,

Leumas could enable brands, CDMOs, and innovators to manufacture oncology, endocrine, and rare disease therapeutics with unmatched agility, compliance, and cost-efficiency.